References

(Hyperlinks to references in text)

  1. Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. Elsevier Ltd; 2011;12:353–60.
  2. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843–54.
  3. Knegjens J, Hauptmann M. Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head Neck. 2011;33:375–82.
  4. Gasparini G, Bevilacqua P, Bonoldi E, Testolin A, Galassi A, Verderio P, et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin cancer Res. 1995;1:1375–83.
  5. Rios Velazquez E, Hoebers F, Aerts HJWL, Rietbergen MM, Brakenhoff RH, Leemans RC, et al. Externally validated HPV-based prognostic nomogram for oropharyngeal carcinoma patients yields more accurate predictions than TNM staging. Radiother Oncol. Elsevier Ireland Ltd; 2014;113:324–30.
  6. Begg AC. Predicting recurrence after radiotherapy in head and neck cancer. Semin Radiat Oncol. Elsevier Inc.; 2012;22:108–18.
  7. Björk-Eriksson T, West C, Karlsson E, Mercke C. Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int J Radiat Oncol • Biol • Phys. 2000;46:13–9.
  8. Amundson S a, Do KT, Vinikoor LC, Lee RA, Koch-Paiz C a, Ahn J, et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res. 2008;68:415–24.
  9. Torres-Roca JF, Eschrich S, Zhao H, Bloom G, Sung J, McCarthy S, et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res. 2005;65:7169–76.
  10. Hall JS, Iype R, Senra J, Taylor J, Armenoult L, Oguejiofor K, et al. Investigation of radiosensitivity gene signatures in cancer cell lines. PLoS One. 2014;9.
  11. Lim LP, Lau NC, Garrett-engele P, Grimson A. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769–73.
  12. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.
  13. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell. 2005;122:553–63.
  14. Friedman R, Farh K, Burge C, Bartel D. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.
  15. Morozova N, Zinovyev A, Nonne N, Pritchard L, Gorban AN, Harel-bellan A. Kinetic signatures of microRNA modes of action. RNA. 2012;1–21.
  16. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455:58–63.
  17. Niemoeller OM, Niyazi M, Corradini S, Zehentmayr F, Li M, Lauber K, et al. MicroRNA expression profiles in human cancer cells after ionizing radiation. Radiat Oncol. BioMed Central Ltd; 2011;6:29.
  18. Mueller a C, Sun D, Dutta A. The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene. Nature Publishing Group; 2013;32:1164–72.
  19. Liu Y-J, Lin Y-F, Chen Y-F, Luo E-C, Sher Y-P, Tsai M-H, et al. MicroRNA-449a Enhances Radiosensitivity in CL1-0 Lung Adenocarcinoma Cells. PLoS One. 2013;8:e62383.
  20. Lynam-Lennon N, Reynolds J V, Marignol L, Sheils OM, Pidgeon GP, Maher SG. MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J Mol Med. 2012;90:1449–58.
  21. Takkunen M, Grenman R, Hukkanen M, Korhonen M, García de Herreros A, Virtanen I. Snail-dependent and -independent epithelial-mesenchymal transition in oral squamous carcinoma cells. J Histochem Cytochem. 2006;54:1263–75.
  22. Yang M-H, Wu M-Z, Chiou S-H, Chen P-M, Chang S-Y, Liu C-J, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol. 2008;10:295–305.
  23. Grenman R, Burk D, Virolainen E, Wagner JG, Lichter AS, Carey TE. Radiosensitivity of head and neck cancer cells in vitro. A 96-well plate clonogenic cell assay for squamous cell carcinoma. Arch Otolaryngol neck Surg. 1988;114:427–31.
  24. Grénman R, Carey TE, McClatchey KD, Wagner JG, Pekkola-Heino K, Schwartz DR, et al. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer. 1991;67:2741–7.
  25. Carlson M, Falcon S, Pages H, Li N. lumiHumanAll.db: me Human Illumina annotation data (chip lumiHumanAll). R package version 1.18.0;
  26. R-Core-Team (2012). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org;
  27. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
  28. Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, Reczko M, et al. TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res. 2012;40:D222–9.
  29. Grimson A, Farh KK-H, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27:91–105.
  30. Kalluri R, Weinberg RAR. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119.
  31. Diehn M, Cho RW, Lobo N a, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780–3.
  32. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 2007;67:3441–9.
  33. Chi J-T, Wang Z, Nuyten DS a, Rodriguez EH, Schaner ME, Salim A, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006;3:e47.
  34. Starmans MHW, Krishnapuram B, Steck H, Horlings H, Nuyten DS a, van de Vijver MJ, et al. Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer. 2008;99:1884–90.
  35. Glinsky G, Berezovska O, Glinskii A. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005;115:1503–21.
  36. Hui ABY, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W, et al. Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin cancer Res. 2010;16:1129–39.
  37. Jerhammar F, Ceder R, Garvin S, Grénman R, Grafström RC, Roberg K. Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma. Cancer Biol Ther. 2010;10:1244–51.
  38. Holz C, Niehr F, Boyko M, Hristozova T, Distel L, Budach V, et al. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells. Radiother Oncol. Elsevier Ireland Ltd; 2011;101:158–64.
  39. Theys J, Jutten B, Habets R, Paesmans K, Groot AJ, Lambin P, et al. E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol. Elsevier Ireland Ltd; 2011;99:392–7.
  40. Kurrey NK, Jalgaonkar SP, Joglekar A V., Ghanate AD, Chaskar PD, Doiphode RY, et al. Snail and Slug Mediate Radioresistance and Chemoresistance by Antagonizing p53-Mediated Apoptosis and Acquiring a Stem-Like Phenotype in Ovarian Cancer Cells. Stem Cells. 2009;27:2059–68.
  41. Watson J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol. 2013;
  42. Gammon L, Biddle A, Heywood HK, Johannessen AC, Mackenzie IC. Sub-sets of cancer stem cells differ intrinsically in their patterns of oxygen metabolism. PLoS One. 2013;8:e62493.
  43. Chiba N, Comaills V, Shiotani B, Takahashi F, Shimada T, Tajima K, et al. Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proc Natl Acad Sci U S A. 2012;109:2760–5.
  44. Boohaker RJR, Cui X, Stackhouse M, Xu B. ATM-mediated Snail Serine 100 phosphorylation regulates cellular radiosensitivity. Radiother Oncol. 2013;231.
  45. Singh a, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. Nature Publishing Group; 2010;29:4741–51.
  46. Sayan a E, Griffiths TR, Pal R, Browne GJ, Ruddick A, Yagci T, et al. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci U S A. 2009;106:14884–9.
  47. Akalay I, Janji B, Hasmim M, Noman MZ, André F, De Cremoux P, et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res. 2013;73:2418–27.
  48. Rouschop KM a, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K, et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest. 2010;120:127–41.
  49. Iorio M V, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4:143–59.
  50. Birrell GW, Brown J a, Wu HI, Giaever G, Chu AM, Davis RW, et al. Transcriptional response of Saccharomyces cerevisiae to DNA-damaging agents does not identify the genes that protect against these agents. Proc Natl Acad Sci U S A. 2002;99:8778–83.